L’apoptose ou mort cellulaire programmée joue un rôle prépondérant dans l’homéostasie cellulaire. Ce processus est très finement régulé par les protéines de la famille BCL-2 qui contrôlent la perméabilité de membrane mitochondriale externe et la libération du cytochrome c, deux événements majeurs précédant la mort cellulaire. Les protéines anti-apoptotiques de la famille BCL-2 contribuent à la tumorigenèse et sont impliquées dans la résistance des cancers aux molécules chimiothérapeutiques ; à ce titre, elles représentent des cibles importantes pour le développement de nouvelles thérapies. BCL2A1 est un membre anti-apoptotique de la famille BCL-2 impliqué dans la chimiorésistance de nombreuses tumeurs. La protéine BCL2A1 a pour caractéristique d’avoir une demi-vie courte due à sa dégradation constitutive par le système ubiquitine-protéasome. Ceci régule la stabilité et la fonction anti-apoptotique de BCL2A1 et représente un mécanisme suppresseur de tumeur majeur. Cependant, les enzymes qui contrôlent les modifications post-traductionnelles impliquées dans l’ubiquitination et la dégradation de BCL2A1 demeurent, à ce jour, inconnues. Dans la présente thèse, nous donnons un aperçu des acteurs et des mécanismes impliqués dans la régulation de l’ubiquitination de BCL2A1. Nous présentons des preuves que TRIM28 est une E3 ubiquitine-ligase pour BCL2A1. En effet, les protéines TRIM28 et BCL2A1 endogènes interagissent ensemble au niveau des mitochondries et la déplétion de TRIM28 diminue l’ubiquitination de BCL2A1. Nous montrons aussi que TRIM17 stabilise BCL2A1 en empêchant son interaction avec TRIM28 et son ubiquitination médiée par TRIM28, et que l’activité de GSK3 est impliquée dans l’inhibition de la dégradation de BCL2A1. Ainsi, BCL2A1 et son proche homologue MCL-1 sont régulés par des facteurs communs mais de façon opposé. Finalement, la surexpression de TRIM28 ou l’inactivation de TRIM17 diminue le niveau protéique de BCL2A1 et restaure la sensibilité des cellules de mélanomes aux thérapies utilisant des inhibiteurs de la kinase BRAF. Globalement, nos résultats décrivent un rhéostat moléculaire au sein duquel deux protéines de la famille TRIM régulent de façon antagoniste la stabilité de BCL2A1 et modulent ainsi la mort cellulaire. / Apoptosis or programmed cell death plays a crucial role in tissue homeostasis and is regulated by the Bcl-2 proteins, which control mitochondria membrane permeability and cytochrome c release, two events that precede cell demise. Anti-apoptotic Bcl-2 family members can contribute to tumorigenesis and cause resistance to anti-cancer regimens, therefore representing important targets for novel therapeutics. BCL2A1 is an anti-apoptotic member of the BCL-2 family that contributes to chemoresistance in a subset of tumors. BCL2A1 has a short half-life due to its constitutive processing by the ubiquitin-proteasome system. This constitutes a major tumor-suppressor mechanism regulating BCL2A1 function. However, the enzymes involved in the regulation of BCL2A1 protein stability are currently unknown. Here we provide the first insight into the regulation of BCL2A1 ubiquitination. We present evidence that TRIM28 is an E3 ubiquitin-ligase for BCL2A1. Indeed, endogenous TRIM28 and BCL2A1 bind to each other at the mitochondria and TRIM28 knock-down decreases BCL2A1 ubiquitination. We also show that TRIM17 stabilizes BCL2A1 by blocking TRIM28 from binding and ubiquitinating BCL2A1, and that GSK3 is involved in the phosphorylation-mediated inhibition of BCL2A1 degradation. BCL2A1 and its close relative MCL1 are thus regulated by common factors but with opposite outcome. Finally, overexpression of TRIM28 or knock-out of TRIM17 reduced BCLA1 protein levels and restored sensitivity of melanoma cells to BRAF-targeted therapy. Therefore, our data describe a molecular rheostat in which two proteins of the TRIM family antagonistically regulate BCL2A1 stability and modulate cell death.Sommaire

No description available.

In this study, we have characterized some biochemical and electrophoretic features of recombinant 20S Proteasome from a thermoacidophilic archaeon Thermoplasma volcanium. As revealed by SDS-PAGE the 20S Proteasome was composed of two subunits, &amp / #945 / - and &amp / #946 / - subunits with estimated molecular masses of 24 kDa and 23 kDa, respectively. The highest chymotryptic activity was observed over an alkaline pH range (pH 8.0 &ndash / pH 9.0) and the optimum temperature for the activity was determined as 85oC. The heat stability of proteasome was quite high after treatment at 98oC for 30 minutes, 64 % of the activity has still been retained. The highest activity associated with the Thermoplasma volcanium proteasome was found to be peptidylglutamyl peptidase activity. Within the scope of this project, also, we have cloned a 26S Proteasome related Regulatory Subunit gene of Thermoplasma volcanium. For cloning we have followed a PCR based approach. Amplification of 26S Proteasome Regulatory Subunit gene from chromosomal DNA of Tp. volcanium yielded a product of 1419 bp containing an open reading frame of 1128 bp comprising the structural gene. The PCR amplicon was cloned using pDrive vector in E.coli TG-1 cells. Out of ten putative recombinants, three plasmids, E.coli pD1-6, E.coli pD2-3, E.coli pD3-1, were proved to be true recombinants and selected for further characterization by restriction mapping and expression studies. ATPase activities of cell free extracts from both recombinant and non-recombinant E.coli strains were measured and found that ATPase activities in cell free extracts of recombinant strains were 10 times higher than non-recombinants. This result indicates sucessful expression of the cloned regulatory subunit gene with ATPase activity in E.coli.

Doctor of Philosophy / Biochemistry and Molecular Biophysics / Jeroen Roelofs / The proteasome is a large protease in the cell that contributes to the controlled degradation of proteins. This 2.5MDa 26S proteasome complex consists of a 19S regulatory particle (RP) that recognizes substrates and a 20S proteolytic core particle (CP) that hydrolyses substrates. To function optimally all 66 subunits of the proteasome complex need to assemble properly. Efficient and accurate assembly of the proteasome is achieved with the help of proteins that can monitor the quality of the proteasome during pre- and post-assembly processes. The work in this thesis described an investigation into two of such quality control mechanisms. Pba1-Pba2 dimer has been known to facilitate the CP assembly by interacting with the top of the α-ring of CP throughout CP maturation. After CP maturation, RP utilizes same surface to form a CP-RP complex. Our data showed that Pba1-Pba2 binds tightly to the immature CP and prevents RP association. Once matured CP has a reduced affinity for Pba1-Pba2 and shows a higher affinity towards RP, resulting the formation of 26S proteasome complex. Our results imply that during maturation, CP undergoes conformational changes that results in this switch in affinity. Mathematical models indicate that during assembly such an 'affinity switch' quality control mechanism is required to prevent immature CP-RP complex formations. These types of wrong dead end products prevent efficient proteasome complex formation. Proteasomes formed with post-assembly defects are enriched with the proteasome associated protein Ecm29. Here Ecm29 is proposed to function as a quality control factor that inhibits such defective proteasomes to avoid aberrant protein degradation. This would require Ecm29 to preferably bind to mutant proteasomes. While we know Ecm29 interacts with RP as well as CP, we still don’t understand well how it binds to proteasomes holoenzyme. Here, we identify that besides the Rpt5 subunit of RP, Ecm29 binds to alpha7. We showed that conserved acidic residues containing unstructured C-terminal region of the CP subunit alpha7 facilitates the Ecm29-Proteasome interactions. Further mapping revealed the importance of phosphorylation of serine residues at the alpha7 C-terminal tail for Ecm29 interaction. We anticipate that this study leads to identification of specificity of the Ecm29 for the defective proteasomes. Overall this will help us to understand the role of Ecm29 in regulation of defective proteasomes in vivo.

Inflammation plays a crucial role in protecting the host from infection and tissue injury. However, uncontrolled inflammation contributes to the pathogenesis of major auto-inflammatory diseases. Interleukin-1 (IL-1), a pleiotropic pro-inflammatory cytokine, is a pivotal mediator of many of these diseases. The best characterised IL-1 family members, IL-1α and IL-1β, are produced as precursor forms of 31 kDa in size. Both precursors are cleaved and secreted, activating transmembrane IL-1 receptors on IL-1-responsive cells. Many studies that focused on IL-1α have shown that the precursor and processed mature Ct peptide, as well as its N terminus (Nt) form, can elicit a signal. However, with IL-1β, only the processed mature Ct form is known to elicit an inflammatory response and no immunological activity has been attributed to Nt fragments of pro-IL-1β. Therefore, the first objective of this study was to produce recombinant human Nt-IL-1β fragments in bacterial and mammalian expression system to investigate their possible immunomodulatory functions. Recombinant His-tagged N-terminus fragments (10 and 14 kDa) of pro-IL-1β were cloned into the bacterial expression vector pET-22(+) and expressed in E. coli BL21(DE3) followed by purification using three consecutive columns (IMAC, SEC and AEC). Purification analysis of eluted proteins from columns indicated that the recombinant proteins were always co-purified with some other bacterial proteins. The Nt fragments of pro-IL-1β were cloned into the mammalian expression plasmid, pcDNA3.1(+). Expression of these proteins was monitored by transfection of two mammalian cell lines: Human Embryonic Kidney (HEK) 293 cells and monkey kidney cells (COS-7). No protein expression was observed with either construct. These limitations urged us to investigate the expression and degradation of endogenous IL-1 in vitro. Previous studies have shown that the transcription of cytokine genes in response to lipopolysaccharide (LPS) is usually rapid and begins to decline within a few hours after stimulation. The proteasome is the major cellular proteolytic apparatus and controls the turn-over of cellular proteins. We investigated the intracellular stability of IL-1α and IL-1β in LPS-stimulated mouse J774 macrophages and primary mouse bone marrow derived macrophages (BMDMs). Exposure of LPS-stimulated J774 and BMDMs to three different classes of proteasome inhibitors (peptide alhedyde (ALLN), peptide boronate (MG262) and non-peptide inhibitor (β-lactone)) prevented the degradation of intracellular IL-1α and IL-1β in a concentration and time dependent manner. Furthermore, the release of IL-1 into the culture media was not affected by any of these inhibitors in LPS-stimulated J774 cells. However, in LPS-stimulated BMDMs, β-lactone increased the release of both IL-1α and IL-1β and ALLN only increased IL-1α release into culture supernatant compared to control. MG262 had no effect on the release of either. These data suggest that the proteasome plays an important role in controlling the amount of IL-1α and IL-1β by restricting the intracellular levels of these cytokines in activated monocytes and macrophages. Therefore, this study provides evidence in support of the hypothesis that the proteasome is involved in the degradation of IL-1α and IL-1β and may offer a potential therapeutic target in inflammatory diseases.

No description available.

No description available.

Células eucarióticas contêm vários tipos de proteassomo que regulam o processo de degradação de proteína. Proteassomos são proteases multicatalíticas que são responsáveis pela maior parte de degradação não-lisossomal de proteínas em células eucarióticas. As três subunidades catalíticas do proteassomo são &beta;1, &beta;2 e &beta;5. Em condições de stress e resposta imune essas três subunidades são substituídas por &beta;1i, &beta;2i and &beta;5i, respectivamente, para formar o proteassomo imune. Estas três subunidades induzíveis, parecem alterar as especificidades de peptidase do proteassoma imune em células tratadas com IFN-<font face=\"symbol\">g. Nosso objetivo no presente trabalho foi caracterizar um modelo celular para a indução do proteassomo imune, e ainda investigar o repertório peptídeo intracelular produzido por esta forma particular do proteassoma, através da técnica de espectrometria de massas. Em resumo, os nossos dados mostraram um aumento de 3 vezes do peptídeo EL28 derivado da proteína RPT2 em células HeLa tratadas com o IFN-<font face=\"symbol\">g. O peptídeo EL28 pode ser de relevância clínica para o tratamento de distúrbios relacionados com a apresentação de antígenos, visto que ele parece ativar a atividade quimotripsina-like quando incubado com o extrato celular de células HeLa. / Eukaryotic cells contain several types of proteasome regulating the process of protein degradation. The proteasome are responsible for most non - lysosomal protein degradation in eukaryotic cells. The three catalytic subunits of the proteasome are &beta;1, &beta;2 and &beta;5. Under conditions of stress and immune response these three subunits are replaced by &beta;1i, &beta;2i and &beta;5i, respectively, to form the immune proteasome . These three inducible subunits, appear to alter the specificity of the immune proteasome peptidase in cells treated with IFN-<font face=\"symbol\">g. Our aim in this study was to characterize a cellular model for the induction of the immune proteasome, and even investigate the intracellular peptide repertoire produced by this particular form of the proteasome, through the technique of mass spectrometry. In summary, our data showed an increase of 3 times the peptide derived from RPT2 EL28 protein in HeLa cells treated with IFN-<font face=\"symbol\">g. The EL28 peptide may be of clinical relevance for the treatment of disorders related to antigen presentation, since it seems to activate the chymotrypsin-like activity when incubated with the cell extract of HeLa cells.

20S Proteasomen der Leber gehören ausschließlich zur Population der Intermediär-Proteasomen. Chromatographisch sind drei proteasomale Subpopulationen aufgrund unterschiedlicher Oberflächenhydrophobizität trennbar. Diese beinhalten unterschiedliche Mengen der Standard- und Immunountereinheiten und zeigen unterschiedliche spezifische Aktivitäten gegenüber kurzen fluorigenen Peptidsubstraten. Außerdem lassen sie sich deutlich anhand der Schnittfrequenzen bei Hydrolyse von Polypeptidsubstraten unterscheiden. Jede dieser Subpopulationen konnte aufgrund unterschiedlicher Oberflächenladung in bis zu 5 verschiedene 20S Proteasom-Subtypen unterteilt werden, die wiederum unterschiedliche Mengen an Standard- und Immununtereinheiten enthielten. Jeder dieser Subtypen zeigte unterschiedliche Eigenschaften bezüglich der spezifischen Aktivitäten und Hydrolysegeschwindigkeiten von Polypeptidsubstraten. Unterschiede wurden auch bezüglich ihrer Peptid-Spleiß-Aktivitäten nachgewiesen. In der vorliegenden Arbeit wurden darüber hinaus Veränderungen der Spektren proteasomaler Subtypen- und ihrer Eigenschaften im Lebergewebe von 2, 8 und 23 Monate alten Ratten nachgewiesen. Während die Gesamtmenge der Leber-Proteasomen mit steigendem Alter abnahm, nahm die Menge der Subtypen mit integrierten Immununtereinheiten zu. Gleichzeitig kam es zu einer altersabhängigen Zunahme der Hydrolysegeschwindigkeit gegenüber Polypeptide-Substraten sowie veränderten Schnitthäufigkeiten. Die altersabhängigen intramolekularen Umgestaltungen von Leberproteasomen könnten eine funktionelle Anpassung an die altersbedingten zellulären Veränderungen in Verbindung mit Veränderungen der MHC Klasse I Antigen-Präsentation darstellen. / 20S proteasomes isolated from rat liver belong to the population of intermediate type proteasomes. Three subpopulations were separated by chromatography due to their differences in surface hydrophobicity. These subpopulations contain different types of intermediate type proteasomes with standard- and immunosubunits exhibiting distinct specific activities towards short fluorogenic substrates. However, depending on the substrate their hydrolyzing activity of long polypeptide substrates was significantly different. Additional separation of the three 20S proteasome subpopulations due to their different surface charges allowed further resolution of each subpopulation to at least five 20S proteasome subtypes. The subunit composition of these subtypes varied with regard to the content of exchangeable subunits. The pattern of proteolytic activities measured with short fluorogenic peptides differed between the various subtypes as well as the ability to hydrolyze polypeptide substrate. Above all, each subtype displayed a specific pattern regarding the peptide-splice-activity. Furthermore, the present work showed age-dependent alterations in the subtype patterns, which were analyzed in livers of 2, 8 and 23 month old rats. While the total amount of proteasome declines with age, in all subtypes from aged animals standard subunits were widely replaced by immunosubunits. This resulted in a relative increase of immunosubunit-containing proteasomes, paralleled by age-dependent changes regarding the hydrolyzing activity of long polypeptide substrates. Such modifications could have implications on protein homeostasis as well as on MHC class I antigen presentation as part of the immunosenescence process.

Le protéasome est responsable de la dégradation régulée d'une majeure partie des protéines intracellulaires. Cette machinerie multimoléculaire est composée d'un cœur catalytique, le protéasome 20S, qui peut être activé par plusieurs types de protéines régulatrices, en particulier la particule régulatrice 19S ou PA700, les complexes heptamériques formés par les membres de la famille 11S (ou PA28) et PA200. Au cours de ce travail, nous nous sommes focalisés sur PA28gamma, un régulateur nucléaire du protéasome, qui active la dégradation de plusieurs substrats par le protéasome 20S de façon indépendante de l'ubiquitine et de l'ATP. Malgré de multiples études montrant l'implication de PA28gamma dans de nombreux processus cellulaires essentiels tels que le cycle cellulaire, la prolifération, l'apoptose, l'architecture nucléaire, la dynamique de la chromatine, les infections virales et la réponse au stress, ses fonctions exactes ne sont pas encore comprises. De plus, les mécanismes impliqués dans la régulation de l'activité de PA28gamma et de son association avec le protéasome 20S restent mystérieux. Une analyse SILAC des partenaires d'interaction de PA28gamma endogène a révélé l'existence d'un nouveau facteur, non caractérisé, que nous avons appelé PIP30 (PA28gamma Interacting Protein 30 kDa). Le gène PIP30 contient un domaine très conservé chez les Eucaryotes. Nous avons produit et purifié la protéine PIP30 recombinante et montré qu'elle est faiblement structurée, malgré le fait qu'elle puisse se dimériser. Nous avons confirmé, aussi bien in vitro qu'in cellulo, que PIP30 interagit directement et spécifiquement avec PA28gamma. En analysant la co-immunoprécipitation de PA28gamma avec différents mutants tronqués de GFP-PIP30, nous avons pu identifier la séquence de PIP30 responsable de l'interaction avec PA28gamma dans sa partie C-terminale. Nous essayons maintenant d'identifier la séquence de PA28gamma impliquée dans la liaison de PIP30 et de cristalliser le complexe PA28gamma/PIP30. L'élaboration d'un anticorps anti-PIP30 « maison » nous a permis de montrer que PIP30 est une protéine nucléaire stable. Son niveau d'expression diminue en réponse à la déplétion de PA28gamma, ce qui suggère que PIP30 est stabilisée par son interaction avec PA28gamma in cellulo. Nous avons démontré in vitro que PIP30 inhibe partiellement l'activation médiée par PA28gamma des activités de type chymotrypsine et caspase, mais pas trypsine, du protéasome. Cependant, nous avons montré, par une approche ELISA, que PIP30 n'affecte pas la liaison de PA28gamma au protéasome 20S. Par ailleurs, nous avons testé l'effet de PIP30 sur la dégradation de p21 par le complexe PA28gamma/protéasome 20S et observé que PIP30 augmente la vitesse de dégradation de p21 dans ce test. Nos tentatives pour élucider la fonction exacte de PIP30 in cellulo n'ont jusqu'ici pas abouti à une conclusion convaincante. L'ensemble de ces résultats suggère que PIP30 pourrait être impliqué dans le recrutement sélectif des substrats de PA28gamma et/ou dans la modulation de l'activation du protéasome par PA28gamma. / The proteasome is responsible for the regulated degradation of most intracellular proteins. This multi-subunit machinery is composed of a common catalytic core, the 20S proteasome, which can be activated by various types of regulators, notably the 19S regulatory particle or PA700, the heptameric complexes formed by the members of the 11S (or PA28) family and PA200. This work has been focused on PA28gamma, a nuclear regulator of the proteasome, which has been shown to activate degradation of several proteasomal substrates in an ATP- and ubiquitin- independent manner. Despite many evidences revealing the involvement of PA28gamma in many essential cellular processes, such as cell cycle progression, proliferation, apoptosis, nuclear architecture, chromatin dynamics, viral infection and stress response, its exact function(s) remain to be understood. In addition, how PA28gamma activity and association to the 20S proteasome are regulated is completely unclear. A SILAC-based analysis of endogenous PA28gamma interaction partners revealed the existence of a novel, completely uncharacterized protein, which we called PIP30 (PA28gamma Interacting Protein 30 kDa). Evolutionary analysis indicates that PIP30 gene contains a domain highly conserved in Eukaryotes, without any alternative splicing or gene duplication evidences. We produced and purified the recombinant PIP30 protein and showed that it is poorly structured, although it is able to make dimers. We confirmed both in vitro and in cellulo that PIP30 directly and specifically interacts with PA28gamma. By analyzing the co-immunoprecipitation of PA28gamma with various GFP-PIP30 truncation mutants, we identified the sequence of PIP30 responsible for PA28gamma binding in its C-terminal part. Ongoing analyses now focus on the identification of PIP30 binding motif on PA28gamma sequence and the crystallization of the PA28gamma-PIP30 complex. Using homemade anti-PIP30 antibodies, we showed that PIP30 is a stable nuclear protein. Its expression level is decreased in response to PA28gamma depletion, suggesting that it is stabilized by its interaction with PA28gamma in cellulo. We demonstrated in vitro that PIP30 partially inhibits PA28gamma-mediated activation of the chymotrypsin- and caspase-, but not the trypsin-like, activities of the proteasome. However, we showed by an ELISA-based approach that PIP30 does not affect PA28gamma binding to 20S. Considering the limitations of probing proteasome activity with small fluorogenic substrates, we tested the effect of PIP30 on the PA28gamma-dependent proteasomal degradation of in vitro translated p21, a known protein substrate of PA28gamma. We unexpectedly found that PIP30 enhanced the rate of p21 degradation. Our attempts to elucidate the exact functions of PIP30 in cellulo were unsuccessful so far. Altogether, our results suggest that PIP30 could be involved in the selective recruitment of PA28gamma protein substrates and/or modulate PA28gamma-mediated proteasome activation.